Profile
Simon Benita is the founder of Bionanosim (BNS) Ltd.
He holds the titles of Chairman and Chief Executive Officer at the company.
Simon Benita active positions
| Companies | Position | Start |
|---|---|---|
Bionanosim (BNS) Ltd.
 Bionanosim (BNS) Ltd. Pharmaceuticals: MajorHealth Technology Bionanosim (BNS) Ltd. is an Israeli company that specializes in the manufacturing of independent nanocarrier-based drugs for clinical testing. The company is based in Jerusalem, Israel. Rafarm is based in Greece. The company is led by Prof. Simon Benita, who has decades of scientific expertise and proven commercial success in bringing nanoparticle-based products to market. Bionanosim is affiliated with the Hebrew University and has a talented cross-functional team that enables them to target multiple areas of unmet needs simultaneously. Rafarm, on the other hand, is an innovation-driven pharmaceutical company that invests 13%% of net turnover in research and development. The company is a well-established European manufacturer that constantly enhances their expertise in complex pharmaceutical products and invests in high-tech platforms for the development and production of ophthalmics and injectables. The company was founded by Joseph C. Papa and Simon Benita, with Simon Benita serving as the CEO since incorporation. | Chief Executive Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Bionanosim (BNS) Ltd.
Bionanosim (BNS) Ltd. Pharmaceuticals: MajorHealth Technology Bionanosim (BNS) Ltd. is an Israeli company that specializes in the manufacturing of independent nanocarrier-based drugs for clinical testing. The company is based in Jerusalem, Israel. Rafarm is based in Greece. The company is led by Prof. Simon Benita, who has decades of scientific expertise and proven commercial success in bringing nanoparticle-based products to market. Bionanosim is affiliated with the Hebrew University and has a talented cross-functional team that enables them to target multiple areas of unmet needs simultaneously. Rafarm, on the other hand, is an innovation-driven pharmaceutical company that invests 13%% of net turnover in research and development. The company is a well-established European manufacturer that constantly enhances their expertise in complex pharmaceutical products and invests in high-tech platforms for the development and production of ophthalmics and injectables. The company was founded by Joseph C. Papa and Simon Benita, with Simon Benita serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Simon Benita
